HTGM.Q Stock Overview
A life sciences company, focuses on the precision medicine. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
HTG Molecular Diagnostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0002 |
| 52 Week High | US$0.26 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | -33.33% |
| 3 Month Change | 0% |
| 1 Year Change | -84.62% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
HTG Molecular Q2 GAAP loss per share widens, revenue down
Aug 11HTG Molecular Diagnostics amends senior loan facility
Jul 18Is HTG Molecular Diagnostics (NASDAQ:HTGM) Using Debt In A Risky Way?
Dec 10
Is HTG Molecular Diagnostics (NASDAQ:HTGM) Weighed On By Its Debt Load?
Aug 27HTG Molecular completes product design lock for planned transcriptome panel
Jun 14These Analysts Think HTG Molecular Diagnostics, Inc.'s (NASDAQ:HTGM) Sales Are Under Threat
Mar 26What Type Of Returns Would HTG Molecular Diagnostics'(NASDAQ:HTGM) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Jan 20
HTG shares surge after upbeat 2020 revenue forecast
Jan 05HTG Molecular Diagnostics announced 1:15 reverse stock split
Nov 23HTG Molecular Diagnostics (HTGM) Investor Presentation - Slideshow
Nov 18Shareholder Returns
| HTGM.Q | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | -33.3% | -3.7% | -3.5% |
| 1Y | -84.6% | 0.7% | 22.1% |
Return vs Industry: HTGM.Q underperformed the US Healthcare Services industry which returned 3.5% over the past year.
Return vs Market: HTGM.Q underperformed the US Market which returned 24% over the past year.
Price Volatility
| HTGM.Q volatility | |
|---|---|
| HTGM.Q Average Weekly Movement | 6,949.2% |
| Healthcare Services Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HTGM.Q's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: HTGM.Q's weekly volatility has increased from 4015% to 6949% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 54 | John Lubniewski | www.htgmolecular.com |
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel.
HTG Molecular Diagnostics, Inc. Fundamentals Summary
| HTGM.Q fundamental statistics | |
|---|---|
| Market cap | US$2.00 |
| Earnings (TTM) | -US$20.15m |
| Revenue (TTM) | US$6.21m |
0.0x
P/S Ratio0.0x
P/E RatioIs HTGM.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HTGM.Q income statement (TTM) | |
|---|---|
| Revenue | US$6.21m |
| Cost of Revenue | US$11.13m |
| Gross Profit | -US$4.92m |
| Other Expenses | US$15.23m |
| Earnings | -US$20.15m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did HTGM.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 17:26 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HTG Molecular Diagnostics, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Alexander Nowak | Craig-Hallum Capital Group LLC |